Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 (Eprenetapopt) and Azacitidine in Patients with TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia at the 25th European Hematology Association Annual Meeting
12 juin 2020 06h00 HE
|
Aprea Therapeutics
57% CR and 75% ORR rate by IWG criteria in all evaluable MDS patients 12.1 months median OS in intention-to-treat MDS patients with 9.7 months median duration of follow-up 13.7 months median OS...
Onconova Therapeutics Announces Presentation at BIO Digital 2020
08 juin 2020 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., June 08, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat...
Aprea Therapeutics Completes Full Enrollment of Phase 3 Clinical Trial in TP53 Mutant Myelodysplastic Syndromes (MDS)
03 juin 2020 08h00 HE
|
Aprea Therapeutics
Topline data expected by year-end 2020Applications for US and EU regulatory approval planned for 2021 BOSTON, June 03, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a...
Onconova Therapeutics Provides Corporate Update and Reports First Quarter 2020 Financial Results
14 mai 2020 16h05 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., May 14, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Therapeutics Announces Virtual Format for 2020 Annual Meeting of Stockholders
11 mai 2020 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., May 11, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Therapeutics to Provide Corporate Update and First Quarter 2020 Earnings on May 14, 2020
07 mai 2020 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., May 07, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat...
Aprea Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
26 mars 2020 08h00 HE
|
Aprea Therapeutics
BOSTON, March 26, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Onconova Therapeutics to Provide Corporate Update and Full Year 2019 Financial Results
18 mars 2020 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., March 18, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Therapeutics Announces Participation in Two Upcoming International Conferences
18 févr. 2020 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with...
Aprea Therapeutics Receives FDA Breakthrough Therapy Designation for APR-246 in Combination with Azacitidine for the Treatment of Myelodysplastic Syndromes (MDS) with a TP53 Mutation
30 janv. 2020 07h30 HE
|
Aprea Therapeutics
BOSTON, Jan. 30, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...